Pancreatic Stellate Cells Potentiate Proinvasive Effects of SERPINE2 Expression in Pancreatic Cancer Xenograft Tumors
References (27)
- et al.
Identification, culture, and characterization of pancreatic stellate cells in rats and humans
Gastroenterology
(1998) - et al.
Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
Gastroenterology
(2005) - et al.
Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway
Biochem Biophys Res Commun
(2004) - et al.
Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment
Matrix Biol
(2001) - et al.
Phenotypical changes of a human pancreatic adenocarcinoma cell line after selection on laminin-1/nidogen (LM/Ng) substratum
Eur J Cell Biol
(1998) - et al.
Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines
Gastroenterology
(2001) - et al.
Extracellular matrix components regulating glandular differentiation and the formation of basal lamina of ahuman pancreatic cancer cell line in vitro
Exp Cell Res
(1994) - et al.
Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro
Pancreas
(1987) - et al.
Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer
Int J Cancer
(1995) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A
Clowes memorial award lecture. Cancer Res
(1990)
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines
Proc Natl Acad Sci USA
Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta
Cancer Res
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo
Nat Med
Cited by (27)
Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression
2020, PancreatologyCitation Excerpt :Tian and colleagues (2012) have reported that the binding of the fibroblast growth factor receptor (FGFR) expressed on PSCs to its ligand FGF secreted by cancer cells induces an invasive phenotype of pancreatic cancer. Studies on in vivo models have demonstrated the modulatory function by PSCs and their role in potentiating the invasiveness of PC cells expressing serine protease inhibitor nexin2 (SERPINE2) possibly by modulating the ECM production and matrix reorganization in the tumour [62]. Another growth factor pathway of interest in PC, is the HGF-c-MET pathway.
Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases
2019, Translational OncologyCitation Excerpt :We found 68 genes that were consistently up-regulated and 76 that were down-regulated in CRCLM relative to matched primary tumors. From this group of 144 differentially expressed genes, 7 were selected for validation based on the association between mRNA level (using values obtained from the microarray) and clinical outcome (Table 3): lumican, a proteoglycan of the extracellular matrix reported to be overexpressed in colorectal breast, neuroendocrine, and other cancers [21]; tissue inhibitor of metalloproteinase 1 (TIMP1), an inhibitor of matrix metalloproteinases and modulator of other diverse processes in cancer cells [22]; basic helix-loop-helix domain containing B2 (BHLHB2), a transcription factor that is induced by hypoxia within tumors [23]; fibronectin, an abundant extracellular matrix protein that contributes to altered stromal remodeling during tumorigenesis [24]; TM4SF1 (transmembrane 4 superfamily member 1), a tumor-associated antigen that regulates cancer cell motility and invasion [25]; serpine2, an extracellular serine protease that is overexpressed in pancreatic, colon, and stomach cancers that may facilitate invasive processes [26]; and MIG-6, a putative tumor suppressor that negatively regulates the ErbB family of receptor tyrosine kinases [27,28]. To determine whether the expression of the candidate genes identified above as correlating with clinical outcome for unresectable patients with colorectal metastases confined to the liver also applied to patients undergoing potentially curative hepatectomy for CRCLM, we performed qRT-PCR of the 7 candidate genes on CRCLM from 56 additional patients.
Matrix control of pancreatic cancer: New insights into fibronectin signaling
2016, Cancer LettersCitation Excerpt :Stromal cells found within the tumor microenvironment can promote PDA tumorigenicity and chemoresistance by enabling ECM–cancer cell interaction [62,63]. For example, subcutaneous co-injection of pancreatic cancer cells and PSCs resulted in larger tumors compared to those mice that were injected with cancer cells only [64,65]. These co-injected tumors showed an increased fibrotic response and increased cancer cell proliferation.
Pancreatic stellate cells and pancreas cancer: Current perspectives and future strategies
2014, European Journal of CancerThe stromal compartments in pancreatic cancer: Are there any therapeutic targets?
2014, Cancer LettersCitation Excerpt :For example, the expression of EMMPRIN (extracellular matrix metalloproteinase inducer) by cancer cells induces the production of MMP-2 by PSCs resulting in increased invasion of the tumour cells [102]. Also, serine protease inhibitor nexin 1 (SERPINE2) expressed by tumour cells promotes invasion and tumour growth only in presence of PSCs [103]. It is suggested that SERPINE2 mediates this effect through the stimulation of ECM protein expression by PSCs [104].
- 1
Prof. Dr. Thomas M. Gress Division of Gastroenterology and Endocrinology University Hospital Giessen and Marburg, site Marburg Philipps University Marburg, Baldinger Strasse, DE-35043 Marburg (Germany) Tel. +49 6421 28 66 460, Fax +49 6421 28 68 922